USANA Health Sciences, Inc. (USNA) Position Trimmed by Chicago Equity Partners LLC

Share on StockTwits

Chicago Equity Partners LLC decreased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 53.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,025 shares of the company’s stock after selling 6,860 shares during the quarter. Chicago Equity Partners LLC’s holdings in USANA Health Sciences were worth $695,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of USNA. BlackRock Inc. boosted its holdings in USANA Health Sciences by 16.0% in the second quarter. BlackRock Inc. now owns 962,366 shares of the company’s stock valued at $110,961,000 after acquiring an additional 133,076 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in USANA Health Sciences by 59.7% in the second quarter. GSA Capital Partners LLP now owns 59,249 shares of the company’s stock valued at $6,831,000 after acquiring an additional 22,146 shares during the last quarter. Swiss National Bank boosted its holdings in USANA Health Sciences by 6.6% in the second quarter. Swiss National Bank now owns 20,900 shares of the company’s stock valued at $2,410,000 after acquiring an additional 1,300 shares during the last quarter. Systematic Financial Management LP bought a new stake in USANA Health Sciences in the second quarter valued at approximately $1,445,000. Finally, Trexquant Investment LP bought a new stake in USANA Health Sciences in the second quarter valued at approximately $555,000. 56.38% of the stock is owned by institutional investors and hedge funds.

In other USANA Health Sciences news, major shareholder Global Ltd Gull purchased 10,396 shares of the business’s stock in a transaction on Tuesday, December 11th. The shares were purchased at an average cost of $70.70 per share, for a total transaction of $734,997.20. Following the acquisition, the insider now owns 10,921,009 shares of the company’s stock, valued at $772,115,336.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Robert A. Sinnott sold 14,741 shares of the stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $129.05, for a total value of $1,902,326.05. Following the transaction, the insider now owns 7,211 shares in the company, valued at $930,579.55. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 19,117 shares of company stock worth $1,349,965 and have sold 956,575 shares worth $122,692,050. 53.20% of the stock is currently owned by corporate insiders.

USANA Health Sciences stock opened at $123.50 on Friday. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 30.42 and a beta of 0.64. USANA Health Sciences, Inc. has a 52-week low of $55.50 and a 52-week high of $137.95.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.25. The firm had revenue of $301.50 million for the quarter, compared to analysts’ expectations of $278.41 million. USANA Health Sciences had a return on equity of 29.50% and a net margin of 7.16%. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.98 EPS. sell-side analysts anticipate that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.

Separately, Pivotal Research restated a “hold” rating and set a $135.00 price target on shares of USANA Health Sciences in a report on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $135.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Discover Your Risk Tolerance

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply